TCGA-OR-A5L3-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.489
- PEROXISOME+0.320
- FATTY_ACID_METABOLISM+0.313
- ADIPOGENESIS+0.300
- BILE_ACID_METABOLISM+0.295
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.273
- XENOBIOTIC_METABOLISM+0.256
- CHOLESTEROL_HOMEOSTASIS+0.192
- P53_PATHWAY+0.121
- UV_RESPONSE_UP+0.064
Top 10 suppressed
- E2F_TARGETS-0.578
- G2M_CHECKPOINT-0.547
- MITOTIC_SPINDLE-0.401
- HEDGEHOG_SIGNALING-0.349
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.339
- UV_RESPONSE_DN-0.331
- PROTEIN_SECRETION-0.318
- ANGIOGENESIS-0.299
- UNFOLDED_PROTEIN_RESPONSE-0.265
- MYC_TARGETS_V1-0.264
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-4486-01A-01R-1206-07 | — | cohortA2 | 0.875 |
| 2 | SRR4296114 | — | cohortA1 | 0.871 |
| 3 | MDT-AP-2103 | Med | Medulloblastoma | 0.852 |
| 4 | TCGA-GM-A5PV-01A-11R-A28M-07 | — | B | 0.846 |
| 5 | MNG1050 | — | — | 0.830 |
| 6 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.822 |
| 7 | MNG908 | — | — | 0.821 |
| 8 | TCGA-KU-A6H8-01A-21R-A34R-07 | — | — | 0.817 |
| 9 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.817 |
| 10 | BS_9DZ253JY | pilocytic astrocytoma | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.489 | Remibrutinib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.313 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.295 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.273 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.256 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.192 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.121 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.064 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.031 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.005 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.001 | Idelalisib | — uncovered |